Hjem › Endetarmskreft › Florida › Tampa
Kliniske studier for Endetarmskreft i Tampa, FL
9 studier for Endetarmskreft søker deltakere på steder i og rundt Tampa (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RekruttererFase 1
- Moffitt Cancer Center, Tampa
Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy
Rekrutterer
- Tampa General Hospital, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
RekruttererFase 2
- Moffitt Cancer Center, Tampa
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
Rekrutterer
- University of South Florida, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
Endetarmskreft-studier i andre byer
- New York City, NY17 studier
- Boston, MA12 studier
- Houston, TX11 studier
- St. Louis, MO11 studier
- Columbus, OH10 studier
- Los Angeles, CA10 studier
- Nashville, TN9 studier
- Seattle, WA9 studier
- Baldwin Park, CA8 studier
- Salt Lake City, UT8 studier
- Aurora, CO8 studier
- Philadelphia, PA8 studier
Andre studier i Tampa
- Ikke-småcellet lungekreft51 studier
- Brystkreft43 studier
- Kreft (alle typer)39 studier
- Kolorektal kreft34 studier
- Akut myelogen leukemi29 studier
- Metastatisk kreft29 studier
- Lungekreft29 studier
- Pankreaskreft26 studier
- Eggstokkreft21 studier
- Melanom19 studier
- Myelodysplastiske syndromer19 studier
- Prostatakreft18 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.